Published in Drug Metab Dispos on February 03, 2014
Targeting tumor microenvironment with PEG-based amphiphilic nanoparticles to overcome chemoresistance. Nanomedicine (2015) 0.82
Repurposing Drugs in Oncology (ReDO)-itraconazole as an anti-cancer agent. Ecancermedicalscience (2015) 0.82
Thyroid hormone and P-glycoprotein in tumor cells. Biomed Res Int (2015) 0.81
Enhanced antitumoral activity of doxorubicin against lung cancer cells using biodegradable poly(butylcyanoacrylate) nanoparticles. Drug Des Devel Ther (2015) 0.80
The role of transporters in toxicity and disease. Drug Metab Dispos (2014) 0.79
P-glycoprotein mediated drug interactions in animals and humans with cancer. J Vet Intern Med (2015) 0.78
Self-assembling nanoparticles encapsulating zoledronic acid revert multidrug resistance in cancer cells. Oncotarget (2015) 0.78
Zoledronic acid-encapsulating self-assembling nanoparticles and doxorubicin: a combinatorial approach to overcome simultaneously chemoresistance and immunoresistance in breast tumors. Oncotarget (2016) 0.77
Chemotherapy curable malignancies and cancer stem cells: a biological review and hypothesis. BMC Cancer (2016) 0.77
Pharmacokinetic Properties of Anticancer Agents for the Treatment of Central Nervous System Tumors: Update of the Literature. Clin Pharmacokinet (2016) 0.76
Imaging of Metabolic Status in 3D Cultures with an Improved AMPK FRET Biosensor for FLIM. Sensors (Basel) (2016) 0.76
Guizhi Fuling Wan, a Traditional Chinese Herbal Formula, Sensitizes Cisplatin-Resistant Human Ovarian Cancer Cells through Inactivation of the PI3K/AKT/mTOR Pathway. Evid Based Complement Alternat Med (2016) 0.76
Disruption of the association between drug transporter and actin cytoskeleton abolishes drug resistance in hypertrophic scar. Oncotarget (2016) 0.75
Molecular Mimics of Classic P-Glycoprotein Inhibitors as Multidrug Resistance Suppressors and Their Synergistic Effect on Paclitaxel. PLoS One (2017) 0.75
Addressing intra-tumoral heterogeneity and therapy resistance. Oncotarget (2016) 0.75
Nuclear-targeting TAT-PEG-Asp8-doxorubicin polymeric nanoassembly to overcome drug-resistant colon cancer. Acta Pharmacol Sin (2016) 0.75
The Role of Eukaryotic and Prokaryotic ABC Transporter Family in Failure of Chemotherapy. Front Pharmacol (2017) 0.75
In vitro and in silico analysis of the vascular effects of asymmetrical N,N-bis(alkanol)amine aryl esters, novel multidrug resistance-reverting agents. Naunyn Schmiedebergs Arch Pharmacol (2016) 0.75
PARP inhibitors: Clinical utility and possibilities of overcoming resistance. Gynecol Oncol (2017) 0.75
Cytochrome P450/ABC transporter inhibition simultaneously enhances ivermectin pharmacokinetics in the mammal host and pharmacodynamics in Anopheles gambiae. Sci Rep (2017) 0.75
Repurposing itraconazole for the treatment of cancer. Oncol Lett (2017) 0.75
Extreme low dose of 5-fluorouracil reverses MDR in cancer by sensitizing cancer associated fibroblasts and down-regulating P-gp. PLoS One (2017) 0.75
Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer (2002) 15.72
Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science (1992) 8.84
Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell (1986) 8.53
Genetic studies on microbial cross resistance to toxic agents. I. Cross resistance of Escherichia coli to fifteen antibiotics. J Bacteriol (1952) 8.31
A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta (1976) 7.41
A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A (1998) 6.47
Mammalian multidrug resistance gene: complete cDNA sequence indicates strong homology to bacterial transport proteins. Cell (1986) 5.51
Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles. Cell Mol Life Sci (2011) 5.42
Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci U S A (1989) 4.66
Selective laser photo-thermal therapy of epithelial carcinoma using anti-EGFR antibody conjugated gold nanoparticles. Cancer Lett (2005) 4.19
Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature (1985) 3.97
Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res (2002) 3.75
The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med (2001) 3.45
Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol (2005) 3.34
Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch Pharm Res (2005) 3.30
The role of ABC transporters in clinical practice. Oncologist (2003) 3.21
Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol (1989) 2.89
Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem (1990) 2.86
Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res (1982) 2.82
Is the multidrug transporter a flippase? Trends Biochem Sci (1992) 2.68
Membrane microparticles: two sides of the coin. Physiology (Bethesda) (2005) 2.68
Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem (2001) 2.62
Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr Med Chem (2006) 2.55
Fluorescent cellular indicators are extruded by the multidrug resistance protein. J Biol Chem (1993) 2.52
Cellular microparticles: a disseminated storage pool of bioactive vascular effectors. Curr Opin Hematol (2004) 2.42
Cellular microparticles: what are they bad or good for? J Thromb Haemost (2003) 2.41
A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc Natl Acad Sci U S A (2006) 2.36
Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog (1995) 2.25
Cell-derived microparticles in haemostasis and vascular medicine. Thromb Haemost (2009) 2.05
Certain calcium channel blockers bind specifically to multidrug-resistant human KB carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein. J Biol Chem (1987) 1.99
Pleiotropic phenotype of colchicine-resistant CHO cells: cross-resistance and collateral sensitivity. J Cell Physiol (1976) 1.96
Photosensitized labeling of a functional multidrug transporter in living drug-resistant tumor cells. J Biol Chem (1990) 1.86
Adaptive landscapes and emergent phenotypes: why do cancers have high glycolysis? J Bioenerg Biomembr (2007) 1.83
Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours. Drugs (1997) 1.76
P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan. Clin Cancer Res (2007) 1.74
Extracellular membrane vesicles from tumor cells promote angiogenesis via sphingomyelin. Cancer Res (2002) 1.73
Characterization of nanoparticles for therapeutics. Nanomedicine (Lond) (2007) 1.62
Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer. Curr Opin Pharmacol (2006) 1.57
Platelet microparticles: a wide-angle perspective. Crit Rev Oncol Hematol (1999) 1.50
Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol (1987) 1.50
Matrix-degrading proteinases are shed in membrane vesicles by ovarian cancer cells in vivo and in vitro. Clin Exp Metastasis (1999) 1.46
Urokinase plasminogen activator and gelatinases are associated with membrane vesicles shed by human HT1080 fibrosarcoma cells. J Biol Chem (1997) 1.45
Effect of nifedipine on adiponectin in hypertensive patients with type 2 diabetes mellitus. J Hum Hypertens (2006) 1.45
Characterization of phosphorylation-defective mutants of human P-glycoprotein expressed in mammalian cells. J Biol Chem (1996) 1.43
Cancer's sweet tooth. Cancer Cell (2006) 1.43
Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer (2005) 1.40
Analysis of the tangled relationships between P-glycoprotein-mediated multidrug resistance and the lipid phase of the cell membrane. Eur J Biochem (2000) 1.40
Circumvention of vincristine and Adriamycin resistance in vitro and in vivo by calcium influx blockers. Cancer Res (1983) 1.39
Membrane microparticles mediate transfer of P-glycoprotein to drug sensitive cancer cells. Leukemia (2009) 1.37
Transferrin-containing, cyclodextrin polymer-based particles for tumor-targeted gene delivery. Bioconjug Chem (2003) 1.35
Drug resistance: still a daunting challenge to the successful treatment of AML. Drug Resist Updat (2012) 1.35
Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. Biochim Biophys Acta (2002) 1.34
pH-Responsive nanoparticles for drug delivery. Mol Pharm (2010) 1.33
Resistance to chemotherapy in cancer: a complex and integrated cellular response. Pharmacology (2008) 1.32
Photoaffinity labeling of the multidrug-resistance-related P-glycoprotein with photoactive analogs of verapamil. Proc Natl Acad Sci U S A (1988) 1.32
pH-sensitive membrane peptides (pHLIPs) as a novel class of delivery agents. Mol Membr Biol (2010) 1.29
Cerebral malaria: role of microparticles and platelets in alterations of the blood-brain barrier. Int J Parasitol (2006) 1.29
Procoagulant activity associated with plasma membrane vesicles shed by cultured tumor cells. Cancer Res (1983) 1.29
Nanoparticle therapeutics: a personal perspective. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2010) 1.28
The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions. J Clin Pharmacol (1999) 1.28
Function and role of microparticles in various clinical settings. Thromb Res (2008) 1.28
Protein kinase C phosphorylates P-glycoprotein in multidrug resistant human KB carcinoma cells. J Biol Chem (1990) 1.27
Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance. J Clin Oncol (1998) 1.26
Endosomes, lysosomes: their implication in gene transfer. Adv Drug Deliv Rev (2000) 1.24
Liposome imaging agents in personalized medicine. Adv Drug Deliv Rev (2012) 1.23
ABC transporters and drug resistance in leukemia: was P-gp nothing but the first head of the Hydra? Leukemia (2007) 1.21
Molecular pathways: regulation and therapeutic implications of multidrug resistance. Clin Cancer Res (2012) 1.20
Induction by verapamil of a rapid increase in ATP consumption in multidrug-resistant tumor cells. FASEB J (1988) 1.16
Inhibition of ABCB1 (MDR1) expression by an siRNA nanoparticulate delivery system to overcome drug resistance in osteosarcoma. PLoS One (2010) 1.16
A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine. Clin Cancer Res (2009) 1.15
Microparticle-associated nucleic acids mediate trait dominance in cancer. FASEB J (2011) 1.13
Glucose depletion enhances P-glycoprotein expression in hepatoma cells: role of endoplasmic reticulum stress response. Cancer Res (2003) 1.13
Stability and covalent modification of P-glycoprotein in multidrug-resistant KB cells. Biochemistry (1988) 1.11
P-glycoprotein: so many ways to turn it on. J Clin Pharmacol (2007) 1.11
The pharmacokinetics of cell-penetrating peptides. Mol Pharm (2010) 1.10
Vesicle-associated urokinase plasminogen activator promotes invasion in prostate cancer cell lines. Clin Exp Metastasis (2000) 1.09
Inhibition of endothelial activation: a new way to treat cerebral malaria? PLoS Med (2005) 1.09
Identification of specific sites in human P-glycoprotein phosphorylated by protein kinase C. J Biol Chem (1993) 1.07
Protein kinase C-mediated phosphorylation does not regulate drug transport by the human multidrug resistance P-glycoprotein. J Biol Chem (1996) 1.06
Molecular mechanisms of endocytosis. Cell (1997) 1.06
Microparticle conferred microRNA profiles--implications in the transfer and dominance of cancer traits. Mol Cancer (2012) 1.05
Formation of procoagulant microparticles and properties. Thromb Res (2010) 1.05
Protection against cerebral malaria by the low-molecular-weight thiol pantethine. Proc Natl Acad Sci U S A (2008) 1.04
A pharmacophore for human pregnane X receptor ligands. Drug Metab Dispos (2002) 1.03
New insight into p-glycoprotein as a drug target. Anticancer Agents Med Chem (2013) 1.03
Signal transduction pathways and transcriptional mechanisms of ABCB1/Pgp-mediated multiple drug resistance in human cancer cells. J Int Med Res (2012) 1.02
P-glycoprotein stability is affected by serum deprivation and high cell density in multidrug-resistant cells. J Cell Physiol (1995) 1.02
Emerging metabolic targets in cancer therapy. Front Biosci (Landmark Ed) (2011) 1.02
Antitumor agents 260. New desmosdumotin B analogues with improved in vitro anticancer activity. J Med Chem (2008) 1.00
Molecular and magnetic resonance imaging: The value of immunoliposomes. Adv Drug Deliv Rev (2009) 1.00
Therapeutic efficacy and safety of paclitaxel/lonidamine loaded EGFR-targeted nanoparticles for the treatment of multi-drug resistant cancer. PLoS One (2011) 1.00
Expression of ATP-binding cassette membrane transporters in rodent and human sertoli cells: relevance to the permeability of antiretroviral therapy at the blood-testis barrier. J Pharmacol Exp Ther (2011) 1.00
Action of calcium antagonists on multidrug resistant cells. Specific cytotoxicity independent of increased cancer drug accumulation. Biochem Pharmacol (1987) 1.00
Breast cancer-derived microparticles display tissue selectivity in the transfer of resistance proteins to cells. PLoS One (2013) 0.99
Identification of the major phosphorylation domain of murine mdr1b P-glycoprotein. Analysis of the protein kinase A and protein kinase C phosphorylation sites. J Biol Chem (1993) 0.98
Inhibition of Wnt/β-catenin signaling downregulates P-glycoprotein and reverses multi-drug resistance of cholangiocarcinoma. Cancer Sci (2013) 0.98
In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity on CYP-450 (Part 2). Bioorg Med Chem (2007) 0.98
Patterns of cross-resistance to the antifolate drugs trimetrexate, metoprine, homofolate, and CB3717 in human lymphoma and osteosarcoma cells resistant to methotrexate. Cancer Res (1983) 0.98
Comparative proteomic analysis of paclitaxel sensitive A2780 epithelial ovarian cancer cell line and its resistant counterpart A2780TC1 by 2D-DIGE: the role of ERp57. J Proteome Res (2009) 0.98
Computational models for predicting substrates or inhibitors of P-glycoprotein. Drug Discov Today (2011) 0.98
Fluticasone uptake across Calu-3 cells is mediated by salmeterol when deposited as a combination powder inhaler. Respirology (2013) 1.38
Glioma microvesicles carry selectively packaged coding and non-coding RNAs which alter gene expression in recipient cells. RNA Biol (2013) 1.26
Microparticle-associated nucleic acids mediate trait dominance in cancer. FASEB J (2011) 1.13
Microparticle conferred microRNA profiles--implications in the transfer and dominance of cancer traits. Mol Cancer (2012) 1.05
Breast cancer-derived microparticles display tissue selectivity in the transfer of resistance proteins to cells. PLoS One (2013) 0.99
Dynamic and intracellular trafficking of P-glycoprotein-EGFP fusion protein: Implications in multidrug resistance in cancer. Int J Cancer (2004) 0.95
Time- and passage-dependent characteristics of a Calu-3 respiratory epithelial cell model. Drug Dev Ind Pharm (2010) 0.93
Liposomal nanoparticles control the uptake of ciprofloxacin across respiratory epithelia. Pharm Res (2012) 0.89
Modulation of P-glycoprotein-mediated anticancer drug accumulation, cytotoxicity, and ATPase activity by flavonoid interactions. Nutr Cancer (2011) 0.86
Chronic obstructive pulmonary disease: patho-physiology, current methods of treatment and the potential for simvastatin in disease management. Expert Opin Drug Deliv (2011) 0.85
Characterization of PXR mediated P-glycoprotein regulation in intestinal LS174T cells. Pharmacol Res (2010) 0.84
Ras/Raf/MEK/ERK pathway is associated with lung metastasis of osteosarcoma in an orthotopic mouse model. Anticancer Res (2011) 0.84
Microparticles mediate MRP1 intercellular transfer and the re-templating of intrinsic resistance pathways. Pharmacol Res (2013) 0.84
Cell-derived microparticles: new targets in the therapeutic management of disease. J Pharm Pharm Sci (2013) 0.84
Epithelial profiling of antibiotic controlled release respiratory formulations. Pharm Res (2011) 0.83
Cellular communication via microparticles: role in transfer of multidrug resistance in cancer. Future Oncol (2014) 0.82
Microparticle drug sequestration provides a parallel pathway in the acquisition of cancer drug resistance. Eur J Pharmacol (2013) 0.81
Fabrication of Curcumin Micellar Nanoparticles with Enhanced Anti-Cancer Activity. J Biomed Nanotechnol (2015) 0.80
Deposition, diffusion and transport mechanism of dry powder microparticulate salbutamol, at the respiratory epithelia. Mol Pharm (2012) 0.80
Ciprofloxacin is actively transported across bronchial lung epithelial cells using a Calu-3 air interface cell model. Antimicrob Agents Chemother (2013) 0.80
Effect of short-term morphine exposure on P-glycoprotein expression and activity in cancer cell lines. Oncol Rep (2004) 0.78
Multiple dosing of simvastatin inhibits airway mucus production of epithelial cells: implications in the treatment of chronic obstructive airway pathologies. Eur J Pharm Biopharm (2013) 0.78
ABCB1 (P-glycoprotein) reduces bacterial attachment to human gastrointestinal LS174T epithelial cells. Eur J Pharmacol (2012) 0.77
Targeting microparticle biogenesis: a novel approach to the circumvention of cancer multidrug resistance. Curr Cancer Drug Targets (2015) 0.76
Modification of disodium cromoglycate passage across lung epithelium in vitro via incorporation into polymeric microparticles. AAPS J (2011) 0.76
Salbutamol sulfate absorption across Calu-3 bronchial epithelia cell monolayer is inhibited in the presence of common anionic NSAIDs. J Asthma (2013) 0.75
An analysis of the therapeutic benefits of genotyping in pediatric hematopoietic stem cell transplantation. Future Oncol (2015) 0.75